Company Filing History:

8 out of 46

Icn Pharmaceuticals, Inc.

patents

1 out of 1,035

Isis Pharmaceuticals, Inc.

Valeant Pharmaceuticals North America

patents

Years Active: 1997-2009

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7638496 - Nucleoside analogs with carboxamidine modified monocyclic base (2009-12-29),

2. 6613896 - Method of producing tiazofurin and other C-nucleosides (2003-09-02),

3. 6573248 - Monocyclic L-nucleosides, analogs and uses thereof (2003-06-03),

4. 6552183 - Moncyclic L-nucleosides analogs (2003-04-22),

5. 6423695 - Cytokine related treatments of disease (2002-07-23),

6. 6262241 - Compound for detecting and modulating RNA activity and gene expression (2001-07-17),

7. 6211201 - Multivalent salts of pyridostigmine and related compounds (2001-04-03),

8. 6130326 - Monocyclic L-Nucleosides, analogs and uses thereof (2000-10-10),

9. 5969135 - Oligonucleotide analogs with an amino acid or a modified amino alcohol (1999-10-19),

10. 5907036 - Procedures for obtaining ribo-C-nucleosides (1999-05-25),

11. 5681940 - Sugar modified nucleosides and oligonucleotides (1997-10-28),

Title: The Innovative Contributions of Kandasamy Ramasamy

Introduction

Kandasamy Ramasamy, based in Laguna Hills, CA, is a prominent inventor with a remarkable portfolio comprising 11 patents. His innovative work primarily focuses on advancements in pharmaceutical compositions and methods of synthesizing complex nucleoside compounds.

Latest Patents

Among his latest patents, Ramasamy has introduced groundbreaking contributions such as:

1. **Nucleoside Analogs with Carboxamidine Modified Monocyclic Base**: This patent discloses novel nucleoside analog compounds that are potentially valuable in treating infections, infestations, neoplasms, and autoimmune diseases. Furthermore, these compounds can modulate various aspects of the immune system, including Type 1 and Type 2 activity.

2. **Method of Producing Tiazofurin and Other C-Nucleosides**: In this method, C-nucleosides are synthesized through a novel process involving the derivatization of sugar in one step to create a heterocycle, with subsequent aromatization. The patent outlines several embodiments, including converting cyano sugars into thiocarboxamides and forming azole rings through various chemical reactions.

Career Highlights

Ramasamy has made significant contributions to the field of pharmaceuticals through his tenure at reputable companies such as Icn Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. His work has contributed to the advancement of treatments and therapeutic methodologies.

Collaborations

Throughout his career, Ramasamy has collaborated with notable colleagues, including Robert C Tam and Devron R Averett. These partnerships have likely fostered creativity and innovation, further enhancing the impact of their collective work in the pharmaceutical sector.

Conclusion

Kandasamy Ramasamy stands out as an influential inventor in the pharmaceutical industry, with a rich history of developing impactful technologies and methodologies. His work has the potential to change therapeutic approaches and improve health outcomes for numerous medical conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com